AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00786643
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
Trial: NCT01807182
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00711308
Drug: acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acenocoumarol for 6 months
Trial: NCT02341456
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
Trial: NCT01077362
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections
Trial: NCT03893825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
Trial: NCT00696488
Drug: Fluorouracil 0.5%
RxNorm normalized name: FLUOROURACIL 0.5% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
Trial: NCT02390843
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
Trial: NCT02390843
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
Trial: NCT02354859
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
Trial: NCT05278052
Drug: Standard maintenance therapy as decided by the treating medical oncologist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard maintenance therapy/Observation
Trial: NCT04139915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT02696330
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
Trial: NCT00507741
Drug: Ertafolide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03781115
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non drug oral placebo capsule will be given as a control
Trial: NCT00773955
Drug: R-(-)-gossypol acetic acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02487940
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Trial: NCT02706847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT01854606
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a Protein Kinase C Inhibitor
Trial: NCT00541905
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
Trial: NCT01575873
Drug: Placebo for risendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once a day
Trial: NCT01575873
Drug: Risendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once a day
Trial: NCT01674933
Drug: Duraphat® Fluoride Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
Trial: NCT01247493
Drug: induction chemotherapy (fludarabine, cytarabine, idarubicin)
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine, cytarabine, idarubicin
Trial: NCT04325633
Drug: 1: Naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
Trial: NCT04325633
Drug: 2: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT00407784
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03288441
Drug: Hold
RxNorm normalized name: Hold DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hold antithrombotic therapy
Trial: NCT03180944
Drug: 1.2% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Trial: NCT03180944
Drug: 1.0% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Trial: NCT03180944
Drug: 0.8% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Trial: NCT03180944
Drug: 0.6% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Trial: NCT03180944
Drug: 0.4% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Trial: NCT02432651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
Trial: NCT01721954
Drug: FOLFOX6m
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04122547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet oral od
Trial: NCT02286453
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
Trial: NCT02803320
Drug: SPF 50 Y65 110 (BAY 987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
Trial: NCT03827447
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
Trial: NCT00649740
Drug: Topamax® Sprinkle Capsule 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, single dose fasting
Trial: NCT00002474
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03288441
Drug: Intermediate dose antithrombotic
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
Trial: NCT02975076
Drug: Sanchitongshu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
Trial: NCT02975076
Drug: placebo of Sanchitongshu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
Trial: NCT00664664
Drug: APD125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
Trial: NCT00664664
Drug: APD125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
Trial: NCT00664664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft gelatin capsule, daily dosing for up to 3 weeks
Trial: NCT01383330
Drug: DW-ES(B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625mg
Trial: NCT02888236
Drug: LEO 32731
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00675506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg sub-cutaneous injections once daily for 12 months
Trial: NCT00936221
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules, 75mg twice daily
Trial: NCT00223210
Drug: PLacebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01500993
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
Trial: NCT03452865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (same ml of the study drug)
Trial: NCT02574962
Drug: H.P. Acthar® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02745639
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
Trial: NCT00936221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01844115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982396
Drug: ABC Twice Daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01982396
Drug: 3TC Once Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982396
Drug: 3TC Twice Daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00038441
Drug: DTI-015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTI-015 injected through a catheter into center of brain tumor.
Trial: NCT00993317
Drug: Placebo of CDP870
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given every 2 weeks until Week22 (SC)
Trial: NCT00993317
Drug: CDP870 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
Trial: NCT00993317
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly.
Trial: NCT02231437
Drug: Berodual®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03448536
Drug: Acetaminophen (Tylenol Extra Strength)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg \*2 caplets, orally, single dose
Trial: NCT03566979
Drug: Test naproxen sodium tablet
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 2 test naproxen sodium 220 mg tablets
Trial: NCT03566979
Drug: Commercial naproxen sodium tablet
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 2 naproxen sodium 220 mg tablets
Trial: NCT03566979
Drug: Commercial naproxen sodium liquid gels capsule
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 2 naproxen sodium 220 mg liquid gel capsules
Trial: NCT03566979
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets
Trial: NCT00160082
Drug: Xepol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01856517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00455741
Drug: Estradiol infusion
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
Trial: NCT05774405
Drug: Climara 0.1Mg/24Hr Transdermal System
RxNorm normalized name: Climara 0.1mg/24hr Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol patch is used.
Trial: NCT00299195
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 150 mg po bid x 24 weeks
Trial: NCT00299195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid x 24 weeks
Trial: NCT00482222
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00482222
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00482222
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02737813
Drug: Isobaric marcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric marcaine 2.2 mL for spinal block
Trial: NCT02737813
Drug: Hyperbaric marcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric marcaine 2.2 mL for spinal block
Trial: NCT03876106
Drug: LUT014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT02314351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous form of metoclopramide is in the same appearance with placebo
Trial: NCT02314351
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
Trial: NCT03297502
Drug: Elidel (pimecrolimus) cream 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03297502
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00134355
Drug: PTK787
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04147195
Drug: LYS006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
Trial: NCT00582491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally everyday for 16 days
Trial: NCT02469883
Drug: Sinotecean
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01867047
Drug: ACE-I Cessation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)
Trial: NCT01867047
Drug: ACE-I Continuation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)
Trial: NCT02807974
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-3150 1.25 to 2.5, 5mg, orally
Trial: NCT00765427
Drug: QLT091001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day repeated dose
Trial: NCT01928693
Drug: Vigamox 0.5% Ophthalmic Solution
RxNorm normalized name: Vigamox 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
Trial: NCT00953147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
Trial: NCT02997332
Drug: 5 Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
Trial: NCT01175759
Drug: Skin test panel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Trial: NCT00466609
Drug: Placebo (fluoxetine plus placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus fluoxetine at maximum dosage of 80mg per day
Trial: NCT00085462
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03317847
Drug: Bromfenac 0.09 % Ophthalmic Solution
RxNorm normalized name: bromfenac 0.09 % Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
Trial: NCT03013075
Drug: General Anesthetics
RxNorm normalized name: GENERAL ANESTHETICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02316886
Drug: Optimal Medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00524186
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00524186
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV